Taiwan's Department of Health said Thursday that local patients using the drug Risperdal would not be affected by a ruling in the United States that fined Johnson & Johnson and a subsidiary, the drug's manufacturer, for improperly marketing the drug and downplaying its potential health risks.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
China's 'unification benefits' hold no appeal for Taiwanese: MAC
10/25/2025 10:44 PM - Cross-Strait
Taiwan must rely on strength to secure peace: President Lai
10/25/2025 10:35 PM - Business
Trump wrong to have Taiwan chip on his shoulder: Tech writer
10/25/2025 09:38 PM - Society
Taiwan at least 3 months away from regaining ASF-free status: MOA
10/25/2025 09:23 PM - Business
Sentiment among manufacturers improves for 3rd straight month on AI boom
10/25/2025 08:59 PM